MedPath

DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial

Not Applicable
Completed
Conditions
Cerebral Aneurysm
Interventions
Device: Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils
Registration Number
NCT01943591
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Brief Summary

Endovascular treatment with platinum coils is safe and effective in preventing rebleeding of intracranial aneurysms. Unfortunately, endovascular treatment of aneurysms with coils has been associated with incomplete occlusion at initial treatment (remnant) or at follow-up (recurrence). This in some studies has been as high as 20%. While many such aneurysm remnants or recurrences exhibit benign behavior, many require retreatment to prevent future hemorrhage.

A recent randomized controlled trial of aneurysm coiling revealed that aneurysms between 2 and 9.9 mm diameter were more likely to have an improved angiographic and composite clinical outcome when treated with hydrogel-coated coils, an improvement inferred to result from higher packing density afforded by hydrogel expansion(1). The use of hydrogel coils is associated with technical difficulties related to expansion and limited time for deployment. The investigators theorize that similar results could be achieved by using more voluminous bare platinum coils, leading to improved packing density compared to smaller caliber coils, and thus result in lower incidence of remnants or residuals. The relationship between packing densities and composite clinical endpoints having never been shown in a robust fashion, the investigators therefore propose a randomized clinical trial opposing coiling with soft 15-caliber coils to 10-caliber bare platinum coils in aneurysms varying in size from 3 to 9.9 mm.

To test the hypothesis that 15-caliber coiling systems are superior to standard 10-caliber coils in achieving better composite outcomes, the investigators propose the DELTA trial: Does Embolization with Larger coils lead to better Treatment of Aneurysms trial, a randomized controlled blinded trial with 2 subgroups of 282 patients each, 564 total:

Subgroup 1: Coiled with a maximum proportion of 15-caliber coils as conditions allow Subgroup 2: Coiled with 10-caliber coils.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
210
Inclusion Criteria
  • At least one ruptured or unruptured aneurysms with a dimension ≥ 10 mm (longest axis)
  • for ruptured lesions, patients should be in World Federation of Neurosurgical Societies (WFNS) grade < IV.
  • The anatomy of the lesion is such that endovascular treatment is possible with both types of coils (not necessarily certain or probable)
  • Patient is 18 or older
  • Life expectancy is more than 2 years (able to complete follow-up)
Exclusion Criteria
  • Patients with planned treatment of an associated cerebral arteriovenous malformations
  • When parent vessel occlusion, without simultaneous endosaccular coiling of the aneurysm, is the primary intent of the procedure
  • Any absolute contraindication to endovascular treatment, angiography, or anaesthesia such as severe allergies to contrast or medications

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
10-caliber coilsEndovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coilsEndovascular embolization coiling using standard 10-caliber platinum coils
15-caliber platinum coilsEndovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coilsEndovascular embolization coiling using 15-caliber platinum coils
Primary Outcome Measures
NameTimeMethod
Related MortalityWithin 1 year following coiling

Mortality that precludes follow up

Major Recurrence of Lesion or Presence of Residual Aneurysm1 year

Major radiographic recurrence of the lesion or the presence of a 'residual aneurysm' as judged by core lab

Retreatment of the Same Lesion by Endovascular or Surgical MeansWithin 1 year following coiling

Retreatment of the same lesion by endovascular or surgical means during the follow-up period

Hemorrhage During the Follow-up PeriodWithin 1 year following coiling

Post-treatment hemorrhage experienced during follow-up period.

Initial Treatment FailureWithin 1 year following coiling

Inability to treat aneurysm, either because access to aneurysm is difficult or technical issues.

Related MorbidityWithin 1 year following coiling

Morbidity that precludes follow up

Secondary Outcome Measures
NameTimeMethod
Packing Densitywithin the first 3 days after coiling

Packing density with the number of coils implanted

Modified Rankin Score (mRS) Greater Than 2at 1 year follow-up

Modified Rankin Score (mRS) that is greater than 2 at 1 year follow-up (or at last follow-up, if applicable). Minimum = 0 (no symptoms), maximum = 6 (Deceased).

Procedural Serious Adverse Events (SAEs)Within 6 months following coiling

Procedural-related serious adverse events

Trial Locations

Locations (15)

University of Illinois at Chicago

🇺🇸

Chicago, Illinois, United States

University of Massachusetts Medical School

🇺🇸

Worcester, Massachusetts, United States

Stony Brook University Medical Center (SUNY)

🇺🇸

Stony Brook, New York, United States

University of Tennessee Medical Center

🇺🇸

Knoxville, Tennessee, United States

SUNY Upstate Medical University

🇺🇸

Syracuse, New York, United States

University of Virginia Health System

🇺🇸

Charlottesville, Virginia, United States

West Virginia University Hospital

🇺🇸

Morgantown, West Virginia, United States

Foothills Medical Center

🇨🇦

Calgary, Alberta, Canada

University of Alberta Hospital

🇨🇦

Edmonton, Alberta, Canada

McMaster University, Hamilton General Hospital

🇨🇦

Hamilton, Ontario, Canada

Toronto Western Hospital

🇨🇦

Toronto, Ontario, Canada

Ottawa Hospital

🇨🇦

Ottawa, Ontario, Canada

Centre Hospitalier de l'Université de Montréal

🇨🇦

Montreal, Quebec, Canada

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Queen Elizabeth II Health Sciences Centre

🇨🇦

Halifax, Nova Scotia, Canada

© Copyright 2025. All Rights Reserved by MedPath